Navigation Links
Data Published Today Reveal That Novel Oral Therapy Fostamatinib Demonstrates Positive Response in Rheumatoid Arthritis Patients
Date:9/22/2010

re patients in both the fostamatinib 100mg bid group and the fostamatinib 150mg qd group (67% and 57% respectively) than the placebo group (35%, p<0.001). - The ACR 50* response rates were 43%, 32% and 19% for the fostamatinib 100mg bid group, 150mg qd group and placebo group respectively (p<0.01). The ACR 70* response rates were 28%, 14% and 10% for the fostamatinib 100mg bid group, 150mg qd group and placebo group respectively (p<0.001 for fostamatinib 100mg bid, p=0.34 for fostamatinib 150 mg qd). - In addition, the DAS 28 remission rate was significantly higher in both the fostamatinib 100mg bid group and the fostamatinib 150mg qd group (31% and 21% respectively), compared to the placebo group (7%, p<0.01).

The published data indicates that the most common drug-related adverse events in the study were diarrhea (19% in 100mg bid group, 12% in the 150mg qd group and 3% in the placebo group), upper respiratory infection (15%, 7% and 7% respectively) and neutropenia (6%, 7% and 1% respectively). Hypertension (BP>140/90) occurred more frequently in fostamatinib treated patients than placebo (29% across both fostamatinib groups compared to 17% in placebo group) as had been previously reported. The hypertension generally occurred within the first few weeks of therapy and was responsive to conventional anti-hypertensive medications.

There were a similar proportion of patients who had at least one adverse event (AE) among the placebo group and the fostamatinib groups (65%). Ninety-four percent of eligible patients enrolled in an ongoing long-term open label extension study. The low rate of withdrawals is additional evidence that the adverse events were manageable in the patients studied.

AstraZeneca plans to commence the phase III clinical trial programme for fostamatinib shortly. The phase III programme, called OSKIRA (Oral Syk Inhibition in Rheumatoid Arthritis), is expected to begin in the second half of 2010.

* The AC
'/>"/>

SOURCE AstraZeneca
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. PTC124 Shows Promising Activity in Cystic Fibrosis; Phase 2 Proof-of-Concept Data Published in the Lancet
2. More Evidence Published That Epidemics of Childhood Obesity, Type 2 Diabetes and Metabolic Syndrome are Linked to Immunization
3. Clinical Study of Intermezzo(R) for the Treatment of Middle of the Night Awakening Published in SLEEP
4. Wound Management Technologies, Inc. Announces a Published Case Study
5. Technique for Creating Authentic Rat Embryonic Stem Cells Published in Cell
6. Research Published in Nature Medicine Shows Disruption of Chemokine Interactions Inhibits Atherosclerosis in Mice
7. Data Published in Nature Cell Biology Reveal Novel Function of Drug Target EpCAM in Cancer Cell Signalling
8. Universal Bioenergy, Inc. Expressly Disclaims Any Responsibility for the Content, Accuracy of Information, and Quality of Information Regarding Universal Published by Any Third-Party and Being Disseminated on the Internet
9. International Guidelines for First-Line use of Freelite(TM) in Diagnosis and Management of Multiple Myeloma to be Published in "Leukemia"
10. Pre-Clinical Data on CEA-specific BiTE Antibody Published in Journal of Immunotherapy Demonstrate Potent Control of Tumor Growth
11. Life sticks: UC San Diego bioengineers sticky insights published in journal Science
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... Research and Markets  has announced ... (Biodegradable Polymer, Food & Beverage, Personal Care & ... report to their offering. Lactic ... asymmetrical carbon atom. The main applications of lactic ... beverage, personal care product, and pharmaceutical industries. ...
(Date:8/27/2014)... 2014  Lisa Kulik saw fireworks for the first ... thanks to a groundbreaking retinal implant co-invented by ... at the University of Southern California (USC) Eye Institute. ... Ariz. resident who has retinitis pigmentosa, a ... On June 2, she became the first person west ...
(Date:8/27/2014)... 27, 2014  A novel biomarker for rheumatoid ... better identify early-stage disease, when treatment can often ... a new study in The Journal of Rheumatology. ... DGX ) and other institutions found that ... conventional antibody-serum testing, including rheumatoid factor (RF) and ...
(Date:8/27/2014)... (PRWEB) August 27, 2014 “We are ... technology vendors,” said Ven Thangaraj, CEO of Radiant Sage. ... that are taking the imaging corelab market to a ... corelabs and research organizations to efficiently and effectively manage ... the data to be analyzed and read by trained ...
Breaking Biology Technology:Global Lactic Acid (Biodegradable Polymer, Food & Beverage, Personal Care & Pharmaceutical) Market - Trends & Forecasts to 2019 2USC Eye Institute ophthalmologists implant first FDA-approved Argus II retinal prosthesis in western United States 2USC Eye Institute ophthalmologists implant first FDA-approved Argus II retinal prosthesis in western United States 3USC Eye Institute ophthalmologists implant first FDA-approved Argus II retinal prosthesis in western United States 4USC Eye Institute ophthalmologists implant first FDA-approved Argus II retinal prosthesis in western United States 5Novel Biomarker Detects Early Rheumatoid Arthritis Better than Conventional Methods Alone, According to Journal of Rheumatology Study 2Novel Biomarker Detects Early Rheumatoid Arthritis Better than Conventional Methods Alone, According to Journal of Rheumatology Study 3Novel Biomarker Detects Early Rheumatoid Arthritis Better than Conventional Methods Alone, According to Journal of Rheumatology Study 4Radiant Sage Named to CIOReview List of 100 Most Promising Technology Companies 2
... July 31 Vista Partners announced today,that it ... drug,candidates, which target billion dollar markets, are progressing ... will present Phase 2 results for,Convivia(TM) sometime in ... FDA approval,of Delayed Release (DR) Cysteamine for the ...
... Iceland, July 31 deCODE genetics,Inc. (Nasdaq: DCGN ... quarter,2008 financial results in a press release to be ... market in New York. The company will host a ... and recent,operating highlights on Thursday, August 7, at 8am ...
... 31 InNexus,Biotechnology Inc., (TSX VENTURE: IXS; ... drug development company commercializing the,next generation of ... Linking,(DXL(TM)) technology, will present at IBC,s 13th ... Innovative Therapeutics (DDT) Conference being,held in Boston ...
Cached Biology Technology:Vista Partners Updates Coverage on Raptor Pharmaceuticals Corp. (OTC Bulletin Board: RPTP) 2deCODE genetics Announces Webcast of Conference Call to Discuss Second Quarter 2008 Financial Results 2InNexus Biotechnology CEO and Chief Scientific Officer to Present at IBC's Annual World Congress Conference in Boston on Aug 6th 2
(Date:8/27/2014)... based upon a proxy for impact have been identified ... approach to scientific research. , The researchers from the ... top 100 pathogens affecting humans and the top 100 ... will help governments across the continent plan for risks ... a result of climate change, and for biosecurity. , ...
(Date:8/27/2014)... by the Volunteer Wildfire Services of South Africa as ... warned residents in certain parts of the province on ... A high veld fire danger rating is expected in ... Great Kei and Mnquma area. Strong winds often ... thunderstorms bring lightning strikes and subsequent fire and the ...
(Date:8/27/2014)... Aug. 27, 2014 /PRNewswire-iReach/ -- The IEEE Engineering in ... th Annual International Conference (EMBC,14), this year being ... Chicago, Illinois , from Tuesday, August ... leaders, students, and industry professionals in science, medicine, and ... http://photos.prnewswire.com/prnh/20140827/140333 This year,s conference ...
Breaking Biology News(10 mins):Big data approach identifies Europe's most dangerous human and domestic animal pathogens 2Global Leaders In Science, Medicine, And Engineering Gather For The 36th Annual International Conference Of The IEEE Engineering In Medicine And Biology Society, August 26-30 In Chicago 2Global Leaders In Science, Medicine, And Engineering Gather For The 36th Annual International Conference Of The IEEE Engineering In Medicine And Biology Society, August 26-30 In Chicago 3
... Louis are bringing the minimalist approach to medical ... technology with a smartphone, enabling a compact, mobile ... fits in the palm of a hand. ... of Computer Science and Engineering, and David Zar, ...
... occur under climate change scenarios has led many scientists to ... But a new study in the May issue of ... the types of plants growing in an area could override ... Higuera of Montana State University and his colleagues show that ...
... environmental scientist from the University of East Anglia (UEA) ... contribution to oceanography. Prof Karen Heywood will ... of the European Geophysical Union assembly in Vienna on ... 25 years of successful field work at sea, Prof ...
Cached Biology News:Ultrasound imaging now possible with a smartphone 2Ultrasound imaging now possible with a smartphone 3Plants could override climate change effects on wildfires 2
...
Contains L-glutamine....
... Resolution - Efficiently separates ... to 1000 bp. It ... PCR fragments, small DNA ... enzyme digestion, and double-stranded ...
...
Biology Products: